Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65

Blood

Volumn 94, Issue 9, 1999, Pages 3242-3250

  Sun, Qi ^b   Pollok, Karen E ^b   Burton, Robert L ^b   Dai, Li Jun ^b   Britt, William ^b   Emanuel, David J ^b   Lucas, Kenneth G ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOBLAST; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LYMPHOPROLIFERATIVE DISEASE; MONONUCLEAR CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; VIRUS EXPRESSION;

EID: 0033230330     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.9.3242     Document Type: Article

References (53)

1. Tosato G: The Epstein-Barr virus and the immune system. Adv Cancer Res 49:75, 1987
2. Britt WJ, Alford CA: Cytomegalovirus, in Fields B, Knipe DM, Howley PM (eds): Fields Virology. Philadelphia, PA, Lippincott-Raven, 1996, p 2493
3. Miller W, Flynn P, McCullough J, Balfour HHJ, Goldman, Haake R, McGlave P, Ramsay N, Kersey J: Cytomegalovirus infection after bone marrow transplantation: An association with acute graft-versus-host disease. Blood 67:1162, 1986
4. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, Castro-Malaspina H, Childs BH, Gillio AP, Small TN, Young JW, Kernan NA, O'Reilly RJ: Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 330:1185, 1994
5. Shapiro RS, McClain K, Frizzera G, Gajl-Peczalska KJ, Kersey JH, Blazar, BR, Arthur DC, Patton DF, Greenberg JS, Burke B, Ramsay NKC, McGlave P, Filipovich AH: Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 71:1234, 1988
6. Wingard JR, Piantadosi S, Burns WH, Zahurak ML, Santos GW, Saral R: Cytomegalovirus infections in bone marrow transplant recipients given intensive cytoreductive therapy. Rev Infect Dis 12:S793, 1990 (suppl 7)
7. Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC, Champlin RE: Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 118:179, 1993
8. Zutter MM, Martin PJ, Sale GE, Shulman HM, Fisher L, Thomas ED, Durnam DM: Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 72:520, 1988
9. Meyers JD, Flournoy N, Thomas ED: Cytomegalovirus infection and specific cell-mediated immunity after marrow transplant. J Infect Dis 142:816, 1980
10. Lucas KG, Small TN, Heller G, Dupont B, O'Reilly RJ: The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 87:2594, 1996
11. Lucas KG, Burton RL, Zimmerman SE, Wang J, Cornetta KG, Robertson KA, Lee CH, Emanuel DJ: Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 91:3654, 1998
12. Keever CA, Welte K, Small T, Levick J, Sullivan M, Hauch M, Evans RL, O'Reilly RJ: Interleukin 2-activated killer cells in patients following transplants of soybean lectin-separated and E rosette-depleted bone marrow. Blood 70:1893, 1987
13. Reusser P, Riddell SR, Meyers JD, Greenberg PD: Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78:1373, 1991
14. Riddell SR, Greenberg PD: Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol 13:545, 1995
15. Heslop HE, Ng CY, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM: Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 2:551, 1996
16. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE: Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9, 1995
17. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD: Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 118:173, 1993
18. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA: Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A randomized double-blind study. Blood 88:4063, 1996
19. Salzberger B, Bowden RA, Hackman RC, Davis C, Boeckh M: Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: Risk factors and outcome. Blood 90:2502, 1997
20. Borysiewicz LK, Morris S, Page JD, Sissons JG: Human cytomegalovirus-specific cytotoxic T lymphocytes: Requirements for in vitro generation and specificity. Eur J Immunol 13:804, 1983
21. Schrier RD, Oldstone MB: Recent clinical isolates of cytomegalovirus suppress human cytomegalovirus-specific human leukocyte antigen-restricted cytotoxic T-lymphocyte activity. J Virol 59:127, 1986
22. Riddell SR, Greenberg PD: The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 128:189, 1990
23. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe, KS, Thomas ED, Riddell SR: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 333:1038, 1995
24. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257:238, 1992
25. Rowe M, Young LS, Crocker J, Stokes H, Henderson S, Rickinson AB: Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: Implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med 173:147, 1991
26. Griffiths PD, Grundy JE: Molecular biology and immunology of cytomegalovirus. Biochem J 241:313, 1987
27. Borysiewicz LK, Hickling JK, Graham S, Sinclair J, Cranage MP, Smith GL, Sissons JG: Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J Exp Med 168:919, 1988
28. Gilbert MJ, Riddell SR, Li CR, Greenberg PD: Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus. J Virol 67:3461, 1993
29. Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B, Sissons JG: The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: Frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 70:7569, 1996
30. Gilbert MJ, Riddell SR, Plachter B, Greenberg PD: Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature 383:720, 1996
31. Li C, Yang X, Tu W, Riddell SR: Human cytomegalovirus matrix protein PP150 is efficiently presented as one of target antigens for cytotoxicT lymphocyte recognition. Chin Med J 110:397, 1997
32. McLaughlin-Taylor E, Pande H, Forman SJ, Tanamachi B, Li CR, Zaia JA, Greenberg PD, Riddell SR: Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 43:103, 1994
33. Boppana SB, Britt WJ: Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells. Virology 222:293, 1996
34. Pande H, Campo K, Tanamachi B, Zaia JA: Human cytomegalovirus strain Towne pp65 gene: Nucleotide sequence and expression in Escherichia coli. Virology 182:220, 1991
35. Hawley RG, Lieu FH, Fong AZ, Hawley TS: Versatile retroviral vectors for potential use in gene therapy. Gene Ther 1:136, 1994
36. Danos O, Mulligan RC: Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc Natl Acad Sci USA 85:6460, 1988
37. Markowitz D, Goff S, Bank A: Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167:400, 1988
38. Emanuel D, Peppard J, Stover D, Gold J, Armstrong D, Hammerling U: Rapid immunodiagnosis of cytomegalovirus pneumonia by bronchoalveolar lavage using human and murine monoclonal antibodies. Ann Intern Med 104:476, 1986
39. Sanchez V, Angeletti PC, Engler JA, Britt WJ: Localization of human cytomegalovirus structural proteins to the nuclear matrix of infected human fibroblasts. J Virol 72:3321, 1998
40. Evans TJ, Jacquemin MG, Farrell PJ: Efficient EBV superinfection of group I Burkitt's lymphoma cells distinguishes requirements for expression of the Cp viral promoter and can activate the EBV productive cycle. Virology 206:866, 1995
41. Lu M, Zhang N, Maruyama M, Hawley RG, Ho AD: Retrovirus-mediated gene expression in hematopoietic cells correlates inversely with growth factor stimulation. Hum Gene Ther 7:2263, 1996
42. Diamond DJ, York J, Sun JY, Wright CL, Forman SJ: Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 90:1751, 1997
43. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA: A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants: The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med 324:1005, 1991
44. Stocchi R, Ward KN, Fanin R, Baccarani M, Apperley JF: Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation. Haematologica 84:71, 1999
45. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR: Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83:1971, 1994
46. Morrison LA, Lukacher AE, Braciale VL, Fan DP, Braciale TJ: Differences in antigen presentation to MHC class I-and class II-restricted influenza virus-specific cytolytic T lymphocyte clones. J Exp Med 163:903, 1986
47. Braciale TJ, Morrison LA, Sweetser MT, Sambrook J, Gething MJ, Braciale VL: Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes. Immunol Rev 98:95, 1987
48. Cassell DJ, Schwartz RH: A quantitative analysis of antigen-presenting cell function: Activated B cells stimulate naive CD4 T cells but are inferior to dendritic cells in providing costimulation. J Exp Med 180:1829, 1994
49. Dennig D, Lacerda J, Yan Y, Gasparetto C, O'Reilly RJ: ICAM-1 (CD54) expression on B lymphocytes is associated with their costimulatory function and can be increased by coactivation with IL-1 and IL-7. Cell Immunol 156:414, 1994
50. Gimmi CD, Freeman GJ, Gribben JG, Sugita K, Freedman AS, Morimoto C, Nadler LM: B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci USA 88:6575, 1991
51. Riddell SR, Rabin M, Geballe AP, Britt WJ, Greenberg PD: Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J Immunol 146:2795, 1991
52. Pear WS, Nolan GP, Scott ML, Baltimore D: Production of high-liter helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 90:8392, 1993
53. Naviaux RK, Costanzi E, Haas M, Verma IM: The pCL vector system: Rapid production of helper-free, high-liter, recombinant retroviruses. J Virol 70:5701, 1996